New HAE drug shows promise in Long-Term safety trial

NCT ID NCT04307381

First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study looked at the long-term safety and effectiveness of a drug called donidalorsen for people with hereditary angioedema (HAE), a condition that causes sudden, severe swelling. Twenty adults who had already completed an earlier study received the drug as a shot under the skin for up to 64 weeks. The main goal was to see if the drug was safe over time, and researchers also tracked how well it controlled swelling attacks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ionis Investigative Site

    Scottsdale, Arizona, 85251, United States

  • Ionis Investigative Site

    Santa Monica, California, 90404, United States

  • Ionis Investigative Site

    Plymouth, Minnesota, 55446, United States

  • Ionis Investigative Site

    Cincinnati, Ohio, 45231, United States

  • Ionis Investigative Site

    Hershey, Pennsylvania, 17033, United States

  • Ionis Investigative Site

    Dallas, Texas, 75231, United States

  • Ionis Investigative Site

    Amsterdam, 1105 AZ, Netherlands

Conditions

Explore the condition pages connected to this study.